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COMMENTS ON RECENT MEETINGS 
NIH Psoriasis/Dialysis Workshop Highlights-April 23, 1979 
Based upon the potential beneficial effects of a new form of 
therapy for intractable psoriasis, the NIH was prompted to 
organize and sponsor an informal workshop on psoriasis/di-
alysis in Bethesda on April 23, 1979. Interested nephrologists 
and dermatologists as well as nonphysicians were invited to 
participate. The purpose of this conference was to bring to-
gether the experiences of various people with dialysis in the 
treatment of psoriasis, to determine if there is pathophysiolog-
ical rationale for its use, and to address the question of risk 
benefit ratio in psoriasis. 
Dr. Philip Anderson, (University of Missouri) who co-chaired 
the conference with Dr. Karl Nolph, provided a brief report of 
his experience with peritoneal dialysis. Six of 8 patients with 
very severe plaque-type psoriasis showed a 90% improvement. 
Two had a 50 to 90% improvement. Three out of 3 patients who 
had psoriatic arthritis saw improvement of their arthritis symp-
toms as well. There were no patients in the group of 8 that 
actually got worse. Four patients with pustular psoriasis did not 
respond to peritoneal dialysis. 
Dr. Robert Popovitch (University of Texas, Austin) reviewed 
the principles of peritoneal transport and emphasized that 
peritoneal dialysis has a greater capability than conventional 
hemodialysis for removal of higher molecular weight metabo-
lites. He also discussed activated charcoal perfusion, which is 
capable of removing some substances in blood, possibly those 
associated with psoriasis. 
Dr. Karl Nolph (University of Missouri) discussed the effects 
of peritoneal dialysis on uremics versus psoriatics. Although 
some individuals have considered heparin as being the factor 
responsible for improvement ofpsoriatics on dialysis, Dr. Nolph 
indicated that generally heparin does not play a role in this 
therapy. Peritoneal dialysis has been used without heparin and 
yet provided improvement in psoriasis. His opinion is that in 
the case of peritoneal dialysis for psoriasis, the effect of therapy 
is more likely due to removing a metabolite rather than adding 
something. For example, glucose, used in large amounts in 
peritoneal dialysis, is not a factor. It was pointed out that each 
type of dialysis used is capable of removal of substances nor-
mally ~eabsor?ed by the kidney. Dr. Nolph reported that on 
scr~erun.g of dlal~sate for. trace elements in psoriasis, there was 
a slIght Increase ill bromIde levels; although this also occurred 
in uremics, the levels detected were not as high as in psoriatics. 
Folic acid, vitamin A, and zinc levels remain normal' T cells 
tend to be decreased. ' 
Dr. Donald Lewers (Easton Memorial Hospital Easton 
Maryland) reported on partial clearing of one patient on inter~ 
mittent peritoneal dialysis with even better response when 
placed on continuous peritoneal dialysis. Dr. Lewers encounterd 
many problems with his patient including dehydration, consti-
pation, and peritonitis. Dr. Allen Nissenson (UCLA Center for 
Health Sciences) reported outcomes on 7 patients who had had 
psoriasis for more than 10 yr, and were assigned schedules of 
sham and actual hemodialysis. All of the patients reported 
improvement after at least 2 courses of therapy but objective 
examination revealed no improvement whatsoever in either 
group. Ultimately all of the patients lost interest in this form of 
therapy. An incidental observation indicates the tendency of 
psoriatics to clot their shunts during hemodialysis. He also 
observed complement activation and a decrease in granulocytes 
in dialyzed psoriatics; there is recovery after dialysis. Dr. Nis-
senson concluded his remarks by acknowledging two reports in 
the literature of the onset of psoriasis during dialysis. 
Dr. Kenji Maeda (Nagoya Clinic, Nagoya, Japan) reviewed 
his experience with 13 patients with psoriasis treated by he-
moflitration, a system experimentally used in Japan. All of 
these patients with psoriasis had nail involvement. The patient 
ages ranged from 45 to 71 years. Five patients experienced 
actual remission of their psoriasis. Three patients showed defi-
nite improvement, and 5 patients showed no improvement 
whatsoever. Dr. Maeda also corroborated Dr. Nolph's comment 
that heparin did not seem to be a factor in the response of 
psoriatics to dialysis. His group had to stop the hemoflitration 
method of treatment because of some significant febrile reac-
tions. 
Drs. Julius Kerkay and Philip Bailin (Cleveland Clinic) dis-
cussed the so-called "X-substance" or "psoriasis factor" found 
by gas chromatographic analysis of dialysate of psoriatics. It is 
small molecule of 300-500 daltons that may represent the lipid 
fraction of a larger lipoprotein of approximately 17,000 molec-
ular weight (fatty acids are removed in relatively large quanti-
ties by peritoneal dialysis). They claimed that this low weight 
peptide is found only in the blood of psoriasis patients and not 
in their urine; this may indicate that the molecule is reabsorbed 
by the kidney, and thus not excreted. Dr. Kerkay reported that 
blood concentrations of the factor have been found to decrease 
72 to 90% following dialysis. Their finding appears to correlate 
with the isolation by Dr. Maeda of a peptide with a molecular 
weight of 400 daltons in slices removed from psoriatic nails 
prior to dialysis. The peptide could not be found in the nails for 
a period of time after dialysis. 
Dr. Frederick Port (University of Michigan) reported on a 
survey of 20 patients with psoriasis all of whom had chronic 
renal failure as well. Ten of 20 patients showed some improve-
ment and 5 actually had remarkable remission. It was Dr. Port's 
conclusion that the minority of his patients evidence marked 
improvement. 
At a second presentation Dr. Nolph discussed the cost of 
dialysis. Institutional hemodialysis, hemoflitration and hemo-
perfusion dialysis for chronic renal disease costs approximately 
$25,000 to $30,000 per year. Hemodialysis, peritoneal dialysis at 
home and continuous ambulatory peritoneal dialysis costs ap-
proximately $10,000 to $12,000 per year. The costs for limited 
peritoneal dialysis for psoriasis would be considel'ably less per 
patient year. Although the incidence of peritonitis is less than 
1% in most centers with automated equipment for intermittent 
peritoneal dialysis, psoriatic skin may be responsible for greater 
risk of infection. 
The meeting concluded on a note of cautious optimism. 
Participants agreed that there may be a place for peritoneal 
dialysis treatment of severe, intractable, debilitating psoriasis 
that is resistant to all other therapies available. Future protocol 
design will have to consider whether one type of peritoneal 
dialysis is better than another, whether sham treatments are 
necessary, develop kinetic modeling to determine the number 
of liters needed to remove a certain amount of these 400 
molecular weight toxins per week and carry out a sufficient 
number of treatments to avoid false negatives. Strict double-
blind studies may not be possible. Pre- and post-dialysis sam-
ples from blood and urine will have to be stored and dialysate 
samples should also be saved. The distinctions between J'e-
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sponders and non-responders will also have to be elucidated. 
Within these groups the type of psoriasis, i.e., psoriasis with 
and without renal disease, plaque, pustular etc. must be char-
acterized. Tissue typing of psoriasis/ dialysis patients and mon-
itoring of parathyroid and calcium metabolism during dialysis 
was recommended. 
Dr. Anderson offered the use of the computer facilities at the 
University of Missouri for data collection of the fragmented 
information cWTently available on psoriasis response to dialysis. 
Interested physicians are requested to contact Dr. An~erson to 
contribute their data for a compilation of experience m evalu-
ating this therapy. Participants agreed to assist Dr. Anderson 
in preparing a request for a second NIH conference on this 
subject in approximately 1 yr. 
DEFINITIONS 
Peritoneal Dialysis 
Utilization of the peritoneum as the membrane through 
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which metabolites are flltered. Requires approximately nine 
hours. 
Hemodialysis 
An extra corporeal blood washing technique, utilizing syn-
thetic semi-porous membranes. Takes 3 to 6 hr. 
H emofiltration 
Blo~d is flltered t~'?ugh very porous membranes quickly 
re~ovmg large quantItIes of fluid plus metabolites. Balanced 
flwds are returned by continuous infusion. 
Law'ence H. Miller, M.D. 
Skin Diseases Program Director 
National Institute of Arthritis 
Metabolism, and Digestive Diseases 
National Institutes of Health 
Announcement 
On June 7 and 8, 1980, The College of Medicine. and Dentistry of New Jersey-New Jersey Medical 
School will present, Dermatopathology: A PractIcal Self-Assessment Course coordinated by Clark 
Lambert, M .D. Registration information can be obtained from CMDNJ-OCE, 100 Bergen St., Newark, 
New Jersey 07103, (201) 456-4267. 
